How Ipamorelin works through GHS-R1a
The receptor story is interesting enough on its own. It becomes misleading when every downstream health benefit is treated as automatic.
Stations
What does Ipamorelin peptide do?
Ipamorelin activates GHS-R1a, the ghrelin receptor, on growth-hormone-producing cells in the pituitary. The founding experiments demonstrated release of stored growth hormone in rat pituitary cells, then in living rats and pigs. Intracellular calcium is involved in carrying the activation signal to hormone release.
The pituitary sits below the brain; “somatotroph” is the name for one of its growth-hormone-producing cells. That is the useful anatomical setting. The human intravenous study recorded a discrete growth-hormone pulse peaking at about 40 minutes.
I appreciate a mechanism with a measurable event attached to it. The event here is hormone release. A claim about sleep or tissue recovery has to travel further and be tested in its own right.
Selectivity in the original experiments
The 1998 animal characterization compared growth-hormone release with responses in ACTH and cortisol. Ipamorelin preserved a selective profile at amounts more than 200-fold above its GH ED50. Earlier GHRPs produced more spillover into other hormone responses.
That specificity impressed me before I reached the clinical papers, and it still does. “Selective” describes the hormone pattern measured in those experiments. Chronic cardiovascular effects, glucose regulation and clinical usefulness require additional observations.
The adjective “clean” bothers me more: it quietly invites a wider safety conclusion. The effects page gives the concerns their actual experimental settings.
IGF-1 responses
Growth hormone can stimulate the liver to produce IGF-1. The tempting story is a neat progression from receptor activation to hormone release, then to a growth factor and a desirable physical change. The rat bone-growth study complicates that progression: bones grew faster while total circulating IGF-1 remained unchanged.
That result makes local effects or the pattern of GH pulses plausible questions for further work. It supplies no proof of either explanation. An experiment designed to separate them would answer my next question; the existing result leaves the mechanism partly open.
The GHRH connection
GHRH, growth-hormone-releasing hormone, acts through a different receptor pathway. CJC-1295 and sermorelin are analogues of that signal. The review of GH regulation describes how GHRH and ghrelin-receptor stimulation can work together to amplify hormone release.
This physiology explains interest in the CJC-1295/ipamorelin pairing. Human outcomes for the pair still need a controlled trial. The comparison sections separate that rationale from claims about sleep, weight and recovery.